BACKGROUND: There are few large-scale studies that have examined outcomes for BRCA1/2 carriers who have undergone nipple-sparing mastectomy (NSM). The objective of our study was to examine incidental cancers, operative complications, and locoregional recurrences in BRCA1/2 mutation carriers who underwent NSM for both risk reduction and cancer treatment. METHODS: This was a retrospective review of pathology results and outcomes of 201 BRCA1/2 carriers from two different institutions who underwent NSM from 2007 to 2014. RESULTS: NSM was performed in 397 breasts of 201 BRCA1/2 carriers. One hundred and twenty-five (62.2 %) patients had a BRCA1 mutation and 76 (37.8 %) had a BRCA2 mutation; 150 (74.6 %) patients underwent NSM for risk reduction and 51 (25.4 %) for cancer. Incidental cancers were found in four (2.7 %) of the 150 risk-reduction patients and two (3.9 %) of the 51 cancer patients. The nipple-areolar complex (NAC) was involved with cancer in three (5.8 %) patients. No prophylactic mastectomy had a positive NAC margin. There was loss of the NAC in seven breasts (1.8 %) and flap necrosis in ten (2.5 %) breasts. With a mean follow-up of 32.6 months (1-76 months), there have been four cancer events-three in cancer patients and one in a risk-reduction patient but none at the NAC. CONCLUSION: NSM in BRCA1/2 carriers is associated with a low rate of complications and locoregional recurrence but these patients require long-term follow-up in both the cancer and risk-reduction setting.
BACKGROUND: There are few large-scale studies that have examined outcomes for BRCA1/2 carriers who have undergone nipple-sparing mastectomy (NSM). The objective of our study was to examine incidental cancers, operative complications, and locoregional recurrences in BRCA1/2 mutation carriers who underwent NSM for both risk reduction and cancer treatment. METHODS: This was a retrospective review of pathology results and outcomes of 201 BRCA1/2 carriers from two different institutions who underwent NSM from 2007 to 2014. RESULTS: NSM was performed in 397 breasts of 201 BRCA1/2 carriers. One hundred and twenty-five (62.2 %) patients had a BRCA1 mutation and 76 (37.8 %) had a BRCA2 mutation; 150 (74.6 %) patients underwent NSM for risk reduction and 51 (25.4 %) for cancer. Incidental cancers were found in four (2.7 %) of the 150 risk-reduction patients and two (3.9 %) of the 51 cancerpatients. The nipple-areolar complex (NAC) was involved with cancer in three (5.8 %) patients. No prophylactic mastectomy had a positive NAC margin. There was loss of the NAC in seven breasts (1.8 %) and flap necrosis in ten (2.5 %) breasts. With a mean follow-up of 32.6 months (1-76 months), there have been four cancer events-three in cancerpatients and one in a risk-reduction patient but none at the NAC. CONCLUSION: NSM in BRCA1/2 carriers is associated with a low rate of complications and locoregional recurrence but these patients require long-term follow-up in both the cancer and risk-reduction setting.
Authors: Michael A Howard; Mark Sisco; Katharine Yao; David J Winchester; Ermilo Barrera; Jeremy Warner; Jennifer Jaffe; Peter Hulick; Kristine Kuchta; Andrea L Pusic; Stephen F Sener Journal: J Surg Oncol Date: 2016-07-08 Impact factor: 3.454
Authors: Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King Journal: Curr Probl Surg Date: 2016-11-29 Impact factor: 1.909
Authors: M G Valero; T-A Moo; S Muhsen; E C Zabor; M Stempel; A Pusic; M L Gemignani; M Morrow; V Sacchini Journal: Br J Surg Date: 2020-05-20 Impact factor: 6.939
Authors: Jai Min Ryu; Seok Jin Nam; Seok Won Kim; Se Kyung Lee; Soo Youn Bae; Ha Woo Yi; Sungmin Park; Hyun-June Paik; Jeong Eon Lee Journal: World J Surg Date: 2016-08 Impact factor: 3.352
Authors: James W Jakub; Anne Warren Peled; Richard J Gray; Rachel A Greenup; John V Kiluk; Virgilio Sacchini; Sarah A McLaughlin; Julia C Tchou; Robert A Vierkant; Amy C Degnim; Shawna Willey Journal: JAMA Surg Date: 2018-02-01 Impact factor: 14.766
Authors: Antônio Luiz Frasson; Martina Lichtenfels; Alessandra Anton Borba de Souza; Betina Vollbrecht; Ana Beatriz Falcone; Mônica Adriana Rodriguez Martinez Frasson; Fernanda Barbosa Journal: Breast Cancer Res Treat Date: 2020-03-25 Impact factor: 4.872